New melanoma drug looks promising for Stage III and IV melanoma patients

51% Of Patients Benefited In Phase II Trial.

Forbes (10/30, Fortonbury) reports that in a study published in Annals of Surgical Oncology, a new cancer drug, PV-10,  51% of stage III and IV melanoma patients benefited during a phase II trial, and achieved total cancer disappearance in 26%. In addition, the response tended to be both rapid and dramatic, with a high rate of response. This drug is extremely promising and is much needed for the treatment of advanced melanoma.  Provectus Biopharmaceuticals, Inc. is the company that engineered PV-10.


We want to know what you think. Leave a Reply.

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s